Navigation Links
Vaxart Begins First Oral Vaccine Clinical Trial
Date:6/7/2011

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial. This is the first clinical study evaluating a vaccine that uses the company's novel oral-vaccine platform technology. The trial site is in the United States.

"This first trial in humans is important, because if safety is demonstrated with one vaccine, we can expect that later vaccines using the same Vaxart technology will also be safe," said Vaxart founder and CSO Sean Tucker, Ph.D.

Vaxart's first oral vaccine candidate is designed to protect against H5N1 Avian Influenza. The company also has a pipeline of additional vaccines in development, all based on its oral-delivery technology.

Vaxart also announced the issuance of U.S. patent no. 7,879,602, which provides broad protection for the company's oral-delivery technology. "This patent greatly increases the value of our portfolio because it covers all methods we know of for oral vaccination with a re-usable platform technology," said Vaxart CEO Michael Finney, Ph.D.

About Vaxart TechnologyVaxart leverages proprietary vaccine development and formulation approaches to quickly and efficiently produce oral-delivery vaccines. Central to the company's approach is the incorporation of a unique adjuvant, the vaccine component that enhances immune responses, in the vector that delivers the vaccine antigen. Vaxart's adjuvant works by binding to Toll-Like Receptor 3 to stimulate a potent immune response when the vaccine is taken orally.

Vaxart's technology also enables all of the company's vaccines to use the same vector, or delivery vehicle. Until now, each time an individual received a vector vaccine, a new vector needed to be used. This is because after receiving a vector vaccine, people develop antibodies to the vector itself, and these anti-vector antibodies reduce the effectiveness of later vaccines using the same vector. Vaxart has overcome this issue and demonstrated robust immune responses against multiple targets following a series of oral vaccines, despite using the same delivery vehicle. Vaxart intends to harness its technology to produce new vaccines through a standardized process, with substantially reduced time lines and regulatory risk due to the common technology foundation.

The Vaxart Avian Flu Vaccine ProgramThe H1N1 flu pandemic of 2009 underscored the importance of being prepared for pandemic illnesses. H5N1 Avian flu is endemic in birds in various parts of the world, has repeatedly infected and killed humans, and remains a possible source of an influenza pandemic. Avian flu is an ideal first target for Vaxart's technology. If an outbreak occurs, a precisely-targeted vaccine can be developed and manufactured rapidly, and delivered without the cumbersome and costly logistics necessary for an injected vaccine.

About VaxartVaxart (www.vaxart.com) is a San Francisco-based clinical-stage biotechnology company developing oral-delivery vaccines. The vaccines incorporate a proprietary adjuvant, which boosts the immune response, enabling a vaccine to be effective when taken orally. Moving forward, Vaxart intends to develop next-generation, oral alternatives to existing vaccines with proven market potential.CONTACT:Michele Parisi925/429-1850
'/>"/>

SOURCE Vaxart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
2. Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
3. GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
4. Cellectar, Inc. Begins GMP Production
5. South Africa Begins Introduction of PREVENAR into Childhood Immunization Program
6. Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
7. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
8. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
9. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
11. SemBioSys begins phase I/II trial of insulin produced in plant seeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
Breaking Biology Technology:
(Date:8/23/2017)... -- The general public,s help is being enlisted in what,s thought to be ... on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study ... gut. The project's goal is to help advance scientific knowledge of the ... ...
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
Breaking Biology News(10 mins):